Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson’s Disease by Inhibiting the NF-κB/NLRP3 Pathway

(2022) Shuhan Liu et al.   Frontiers in Pharmacology

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents

(2022) Sangmin Lee et al.   Journal of Hematology & Oncology

Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method

(2022) Yaqiu Wang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

NLRP3 inflammasome in cancer and metabolic diseases

(2021) Bhesh Raj Sharma et al.   NATURE IMMUNOLOGY

Caspase‐3‐mediated GSDME induced Pyroptosis in breast cancer cells through the ROS/JNK signalling pathway

(2021) Ziwen Zhang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Programming inflammatory cell death for therapy

(2021) Shelbi Christgen et al.   PHARMACOLOGY & THERAPEUTICS

ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis

(2021) Rajendra Karki et al.   Cell Reports

Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice

(2020) Jinbo Cheng et al.   Autophagy

The Zα2 domain of ZBP1 is a molecular switch regulating influenza-induced PANoptosis and perinatal lethality during development

(2020) Sannula Kesavardhana et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer

(2020) Yadong Xie et al.   JOURNAL OF CLINICAL INVESTIGATION

The regulation of the ZBP1‐NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis)

(2020) Min Zheng et al.   IMMUNOLOGICAL REVIEWS

The PANoptosome: A Deadly Protein Complex Driving Pyroptosis, Apoptosis, and Necroptosis (PANoptosis)

(2020) Parimal Samir et al.   Frontiers in Cellular and Infection Microbiology

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

(2019) Michael Shafique et al.   ONCOLOGIST

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown

(2018) Hachung Chung et al.   CELL

Eight Novel Mutations of the ADAR1 Gene in Chinese Patients with Dyschromatosis Symmetrica Hereditaria

(2018) Zhuang-li Tang et al.   Genetic Testing and Molecular Biomarkers

Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases

(2018) Junying Yuan et al.   NATURE REVIEWS NEUROSCIENCE

RNA Editing, ADAR1, and the Innate Immune Response

(2017) Qingde Wang et al.   Genes

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia

(2016) Thomas Vercruysse et al.   CLINICAL CANCER RESEARCH

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

(2016) J Etchin et al.   LEUKEMIA

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

(2016) Z A Hing et al.   LEUKEMIA

Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment

(2015) Samira Goldar et al.   Asian Pacific Journal of Cancer Prevention

Isoforms of RNA-Editing Enzyme ADAR1 Independently Control Nucleic Acid Sensor MDA5-Driven Autoimmunity and Multi-organ Development

(2015) Kathleen Pestal et al.   IMMUNITY

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

(2015) A. N. Hata et al.   Cancer Discovery

Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

(2012) Iana M Serafimova et al.   Nature Chemical Biology

Mechanistic insights into editing-site specificity of ADARs

(2012) A. Kuttan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-κB

(2009) Manuele Rebsamen et al.   EMBO REPORTS